Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer (2021)

Peer-Reviewed Study · Passildas-Jahanmohan J, Eymard JC, Pouget M, et al. · April 2021

Passildas-Jahanmohan J et al., 2021-04: Double-blind randomised phase II trial in 50 patients with metastatic castration-resistant prostate cancer: adding 6 g/day curcumin to docetaxel did not improve time to progression (5.3 vs 3.7 months, p = 0.75) and the trial was stopped for futility.

the results from this interim analysis clearly showed that adding curcumin to mCRPC patients' treatment strategies was not efficacious. The study was discontinued on the grounds of futility.

Abstract, Results

Passildas-Jahanmohan J et al., 2021-04: Double-blind randomised phase II trial in 50 patients with metastatic castration-resistant prostate cancer: adding 6 g/day curcumin to docetaxel did not improve time to progression (5.3 vs 3.7 months, p = 0.75) and the trial was stopped for futility. Study type: randomized trial.